Ability Pharmaceuticals, SA

AbilityPharma is a clinical phase 2b biopharmaceutical company focused on developing first-in-class fully differentiated oral targeted anticancer compounds inducing autophagy-mediated cytotoxicity selectively in cancer cells. ABTL0812 causes irreversible cytotoxic autophagy selectively in cancer cells through the induction of ER Stress and Akt blockade. Besides its efficacy as single agent, ABTL0812 has synergistic effect with chemotherapy and has synergistic effect with IO therapies (anti-PD1) and acts on the tumor microenvironment turning cold tumors into hot (immunogenic) tumors. The first drug candidate, ABTL0812, is currently in phase 2b clinical trials in pancreatic cancer in Spain, USA, France, and Israel. The clinical trial will assess the safety and efficacy profile of ABTL0812 in combination with FOLFIRINOX in 150 patients with advanced pancreatic cancer as first-line treatment. According to our conversations with the FDA, the trial could be transformed into phase 3 pivotal trial leading to an early approval expected in 2025. In 2020 we finished the phase 2a first-line clinical trial in endometrial and lung cancer patients with very positive results, showing that ABTL0812 combined with chemotherapy is much superior to chemotherapy alone. Besides that, we are initiating a phase 1/2 trial in the pediatric cancer neuroblastoma.